title: Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.
abstract: OBJECTIVE
  Recommended surveillance for BRCA1 and BRCA2 mutation carriers includes regular mammography and clinical breast examination, although the effectiveness of these screening techniques in mutation carriers has not been established. The purpose of the present study was to compare breast magnetic resonance imaging (MRI) with ultrasound, mammography, and physical examination in women at high risk for hereditary breast cancer.
  
  
  METHODS
  A total of 196 women, aged 26 to 59 years, with proven BRCA1 or BRCA2 mutations or strong family histories of breast or ovarian cancer underwent mammography, ultrasound, MRI, and clinical breast examination on a single day. A biopsy was performed when any of the four investigations was judged to be suspicious for malignancy.
  
  
  RESULTS
  Six invasive breast cancers and one noninvasive breast cancer were detected among the 196 high-risk women. Five of the invasive cancers occurred in mutation carriers, and the sixth occurred in a woman with a previous history of breast cancer. The prevalence of invasive or noninvasive breast cancer in the 96 mutation carriers was 6.2%. All six invasive cancers were detected by MRI, all were 1.0 cm or less in diameter, and all were node-negative. In contrast, only three invasive cancers were detected by ultrasound, two by mammography, and two by physical examination. The addition of MRI to the more commonly available triad of mammography, ultrasound, and breast examination identified two additional invasive breast cancers that would otherwise have been missed.
  
  
  CONCLUSIONS
  Breast MRI may be superior to mammography and ultrasound for the screening of women at high risk for hereditary breast cancer.
authors.affiliation: Division of Medical Oncology, Department of Medical Biophysics, and Centre for Research in Women's Health, Toronto, Ontario, Canada. ellen.warner@tsrcc.on.ca
authors.forename: E
authors.initials: E
authors.lastname: Warner
authors.forename: D B
authors.initials: DB
authors.lastname: Plewes
authors.forename: R S
authors.initials: RS
authors.lastname: Shumak
authors.forename: G C
authors.initials: GC
authors.lastname: Catzavelos
authors.forename: L S
authors.initials: LS
authors.lastname: Di Prospero
authors.forename: M J
authors.initials: MJ
authors.lastname: Yaffe
authors.forename: V
authors.initials: V
authors.lastname: Goel
authors.forename: E
authors.initials: E
authors.lastname: Ramsay
authors.forename: P L
authors.initials: PL
authors.lastname: Chart
authors.forename: D E
authors.initials: DE
authors.lastname: Cole
authors.forename: G A
authors.initials: GA
authors.lastname: Taylor
authors.forename: M
authors.initials: M
authors.lastname: Cutrara
authors.forename: T H
authors.initials: TH
authors.lastname: Samuels
authors.forename: J P
authors.initials: JP
authors.lastname: Murphy
authors.forename: J M
authors.initials: JM
authors.lastname: Murphy
authors.forename: S A
authors.initials: SA
authors.lastname: Narod
mesh_terms: D000328:Adult; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000235:genetics* / Q000473:pathology; D005260:Female; D019398:Genes, BRCA1 / Q000235:genetics; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D008279:Magnetic Resonance Imaging; D008327:Mammography; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics; D010808:Physical Examination; D014157:Transcription Factors / Q000235:genetics; D014463:Ultrasonography
chemical_list: D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors